Literature DB >> 8501245

Two-site comparison of broth microdilution and semisolid agar dilution methods for susceptibility testing of Cryptococcus neoformans in three media.

E Anaissie1, R Shawar, V Paetznick, L G Ensign, Z Witte, M LaRocco.   

Abstract

This study evaluated the inter- and intralaboratory agreement between results of the semisolid agar dilution and broth microdilution methods of antifungal susceptibility testing of Cryptococcus neoformans. Three media were tested in two laboratories. The drugs tested were amphotericin B, flucytosine, itraconazole, fluconazole, and Schering 39304. Analysis by kappa statistics revealed good agreement between the laboratories for the two methods. The highest level of inter- and intralaboratory agreement was observed in RPMI 1640 with L-glutamine followed by Eagle's minimum essential medium and yeast nitrogen broth. The broth microdilution method appears more suitable than the semisolid agar dilution method for testing cryptococci because of its ease in performance, cost, and simplicity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8501245      PMCID: PMC262942          DOI: 10.1128/jcm.31.5.1370-1372.1993

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  19 in total

1.  Improved method for estimation of azole antifungal inhibitory concentrations against Candida species, based on azole/antibiotic interactions.

Authors:  F C Odds; A B Abbott; G Pye; P F Troke
Journal:  J Med Vet Mycol       Date:  1986-08

2.  Comparison of relative susceptibilities of Candida species to three antifungal agents as determined by unstandardized methods.

Authors:  J N Galgiani; J Reiser; C Brass; A Espinel-Ingroff; M A Gordon; T M Kerkering
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

Review 3.  Antifungal susceptibility tests.

Authors:  J N Galgiani
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

4.  Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy.

Authors:  R Horn; B Wong; T E Kiehn; D Armstrong
Journal:  Rev Infect Dis       Date:  1985 Sep-Oct

5.  Influence of culture medium on susceptibility testing with BAY n 7133 and ketoconazole.

Authors:  P D Hoeprich; J M Merry
Journal:  J Clin Microbiol       Date:  1986-08       Impact factor: 5.948

6.  Antimicrobial susceptibility testing of yeasts: a turbidimetric technique independent of inoculum size.

Authors:  J N Galgiani; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1976-10       Impact factor: 5.191

7.  Results of a survey of antifungal susceptibility tests in the United States and interlaboratory comparison of broth dilution testing of flucytosine and amphotericin B.

Authors:  D L Calhoun; G D Roberts; J N Galgiani; J E Bennett; D S Feingold; J Jorgensen; G S Kobayashi; S Shadomy
Journal:  J Clin Microbiol       Date:  1986-02       Impact factor: 5.948

8.  Microtiter broth dilution method for yeast susceptibility testing with validation by clinical outcome.

Authors:  M Radetsky; R C Wheeler; M H Roe; J K Todd
Journal:  J Clin Microbiol       Date:  1986-10       Impact factor: 5.948

9.  Collaborative investigation of broth microdilution and semisolid agar dilution for in vitro susceptibility testing of Candida albicans.

Authors:  R Shawar; V Paetznick; Z Witte; L G Ensign; E Anaissie; M LaRocco
Journal:  J Clin Microbiol       Date:  1992-08       Impact factor: 5.948

10.  Analysis of pH and buffer effects on flucytosine activity in broth dilution susceptibility testing of Candida albicans in two synthetic media.

Authors:  D L Calhoun; J N Galgiani
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

View more
  7 in total

1.  Cryptococcosis in AIDS.

Authors:  P Imwidthaya; N Poungvarin
Journal:  Postgrad Med J       Date:  2000-02       Impact factor: 2.401

2.  A vitamin-free minimal synthetic medium for Cryptococcus neoformans.

Authors:  V Vidotto; S Aoki; G Campanini
Journal:  Mycopathologia       Date:  1996       Impact factor: 2.574

3.  Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: performances of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M27-A methodologies.

Authors:  M Lozano-Chiu; V L Paetznick; M A Ghannoum; J H Rex
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

4.  Correlation of fluconazole MICs with clinical outcome in cryptococcal infection.

Authors:  A I Aller; E Martin-Mazuelos; F Lozano; J Gomez-Mateos; L Steele-Moore; W J Holloway; M J Gutiérrez; F J Recio; A Espinel-Ingroff
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

5.  Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998.

Authors:  M E Brandt; M A Pfaller; R A Hajjeh; R J Hamill; P G Pappas; A L Reingold; D Rimland; D W Warnock
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

6.  In vitro susceptibilities of clinical and environmental isolates of Cryptococcus neoformans to five antifungal drugs.

Authors:  S P Franzot; J S Hamdan
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

7.  Correlation of anti-fungal susceptibility with clinical outcomes in patients with cryptococcal meningitis.

Authors:  Chen-Hsiang Lee; Tzu-Yao Chang; Jien-Wei Liu; Fang-Ju Chen; Chun-Chih Chien; Ya-Fen Tang; Cheng-Hsien Lu
Journal:  BMC Infect Dis       Date:  2012-12-20       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.